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Abstract
The type III TGF-β receptor (TβRIII or betagylcan) is a TGF-β superfamily coreceptor with emerging roles in regu-
lating TGF-β superfamily signaling and cancer progression. Alterations in TGF-β superfamily signaling are common
in colon cancer; however, the role of TβRIII has not been examined. Although TβRIII expression is frequently lost
at the message and protein level in human cancers and suppresses cancer progression in these contexts, here
we demonstrate that, in colon cancer, TβRIII messenger RNA expression is not significantly altered and TβRIII ex-
pression is more frequently increased at the protein level, suggesting a distinct role for TβRIII in colon cancer.
Increasing TβRIII expression in colon cancer model systems enhanced ligand-mediated phosphorylation of p38
and the Smad proteins, while switching TGF-β and BMP-2 from inhibitors to stimulators of colon cancer cell pro-
liferation, inhibiting ligand-induced p21 and p27 expression. In addition, increasing TβRIII expression increased
ligand-stimulated anchorage-independent growth, a resistance to ligand- and chemotherapy-induced apoptosis,
cell migration and modestly increased tumorigenicity in vivo. In a reciprocal manner, silencing endogenous TβRIII
expression decreased colon cancer cell migration. These data support a model whereby TβRIII mediates TGF-β
superfamily ligand-induced colon cancer progression and support a context-dependent role for TβRIII in regulating
cancer progression.
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Introduction
Transforming growth factor β (TGF-β) plays a dichotomous role in
human cancers, functioning both as a tumor suppressor and as a tu-
mor promoter [1]. Many human tumors downregulate or exhibit
mutations in components of the TGF-β signaling pathway, resulting
in functional resistance to the homeostatic functions of the pathway
[2]. Conversely, many late-stage human tumors increase TGF-β ex-
pression, which has a tumor-promoting effect by suppressing im-
mune surveillance, inducing epithelial to mesenchymal transition,
and promoting tumor invasiveness, angiogenesis, and metastasis [2].
This dual role of TGF-β as both a tumor suppressor and tumor pro-
moter remains a fundamental roadblock to effectively targeting the
TGF-β pathway for the treatment of human cancers.
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TGF-β superfamily signaling is regulated and mediated by a co-
receptor, the type III TGF-β receptor (TβRIII or betagylcan), which
binds all three TGF-β isoforms, multiple bone morphogenetic pro-
teins (BMPs), and inhibin [3–6]. TβRIII functions by presenting
ligand to the respective type II and type I TGF-β superfamily recep-
tors, which, upon ligand binding, transphosphorylate to activate the
respective type I TGF-β superfamily receptor [4,7]. This leads to the
phosphorylation and subsequent activation of the Smad transcription
factors, which then interact with Smad4, translocate to the nucleus,
and regulate the transcriptional activity of a variety of TGF-β super-
family responsive genes in a cell type–specific manner [8]. TβRIII
also mediates ligand-dependent and -independent p38 pathway sig-
naling [4,9,10], inhibits nuclear factor κB signaling [11,12], and
activates Cdc42 to regulate cell proliferation and migration [13].
TβRIII inhibits TGF-β superfamily signaling through ectodomain
shedding–mediated generation of soluble TβRIII (sTβRIII), which
has been demonstrated to bind and sequester TGF-β away from its
receptors [4,14].
In normal intestinal epithelium, TGF-β functions as a tumor sup-
pressor through the regulation of cell growth and the induction of
apoptosis [15]. TGF-β superfamily signaling is commonly disrupted
in colon cancer with frequent alterations in components of the TGF-β
superfamily signaling pathways [16–20]. However, studies have
demonstrated that response to TGF-β is dependent on tumor stage,
with TGF-β functioning to inhibit proliferation in early stages of
colon cancer and promoting growth and invasion in later stages
and during tumor progression [21,22]. Colon cancer cells have been
demonstrated to secrete TGF-β and elevated levels of TGF-β1 are
significantly correlated with metastatic disease, disease recurrence,
and decreased survival [24–26]. In addition, TGF-β1 has been dem-
onstrated to promote colon cancer cell proliferation in a Ras-dependent
but Smad-independent manner [27] and to promote Ras-mediated in-
vasiveness in intestinal epithelial cells in a TβRII-dependent manner
[28]. Therefore, in late stages of colon carcinogenesis, TGF-β may
function as a tumor promoter, supporting a dual role for TGF-β sig-
naling in colon cancer progression.
Similarly to TGF-β, BMP expression is increased in colorectal tumors
and correlates with poor prognosis and metastasis [29]. BMPs have di-
verse biologic roles in colon cancer, regulating proliferation, migration,
invasion, apoptosis, and differentiation [30–33]. Overexpression of
BMP4 in the Smad4-deficient cell line, SW480, enhances cell prolifer-
ation, migration, invasiveness, and adhesion [34]. These studies demon-
strate that alterations in TGF-β and BMP signaling play a dual role in
colon carcinogenesis, both inhibiting and promoting colon cancer.
TβRIII is expressed in normal intestinal goblet cells; however, it does
not undergo proper posttranslational modification and is unable to
bind TGF-β1, resulting in insensitivity to TGF-β1–mediated growth
inhibition [35]. In contrast, neighboring absorptive cells, which express
functional TβRIII, are growth-inhibited by TGF-β1, demonstrating
that TβRIII can modulate TGF-β1 signaling in normal colon cells
[35]. Expression of oncogenic Ras in goblet cells restores posttransla-
tional modification of TβRIII and causes these cells to become growth-
stimulated in response to TGF-β1 treatment, suggesting that K-Ras
confers a more aggressive phenotype through alterations in TβRIII post-
translational modifications [35,36]. These data suggest that TβRIII may
play an important role in mediating TGF-β signaling in colon cancer.
Recently, TβRIII expression has been demonstrated to be lost or de-
creased in multiple human cancers, including breast, prostate, ovarian,
pancreatic, and non–small cell lung cancers [37–41]. TβRIII has been
demonstrated to be an important regulator of cell migration, invasion,
cell growth, and angiogenesis, with restoration of TβRIII expression
inhibiting cancer progression [13,37]. Taken together, these data sup-
port a role for TβRIII as a mediator of TGF-β superfamily signaling
during cancer progression. Here, we examined the role of TβRIII in
human colon cancer.
Materials and Methods
TβRIII Gene Expression Analysis on Complementary
DNA Array
An array containing normalized complementary DNA (cDNA)
from colon carcinomas and matched normal tissues (n = 37) (Cancer
Profiling Array; Clontech; Takara Bio Co, Madison, WI) was probed
with a [32P]-labeled cDNA probe for TβRIII following methods rec-
ommended by the manufacturer. The TβRIII cDNA probe was am-
plified by polymerase chain reaction (PCR) using the forward primer
5′ GTAGTGGGTTGGCCAGATGGT 3′ and reverse primer 5′
CTGCTGTCTCCCCTGTGTG 3′. Twenty-five nanograms of pu-
rified PCR products was labeled by random primed DNA labeling
using [α32P]dCTP as per the manufacturer’s protocol (Roche Diag-
nostics, Indianapolis, IN). The labeled cDNA probe was purified on a
BD CHROMA SPIN+STE-100 column (BD Biosciences, Clontech;
Takara Bio Co). Images were acquired using a phosphorimager, and
subsequent data analysis was performed using ImageJ software (Na-
tional Institutes of Health [NIH], Bethesda, MD; http://rsb.info.nih.
gov/ij/). The TβRIII array was normalized to a ubiquitin-probed array.
Tissue Microarray
A custom polyclonal TβRIII antibody (820) was created by im-
munizing rabbits with a GST-fusion protein of the human TβRIII
cytoplasmic domain [37]. Immunohistochemistry for TβRIII was per-
formed on a colon cancer tissue microarray (Cooperative Human Tis-
sue Network, National Cancer Institute, Bethesda, MD) containing
colon carcinomas (n = 323), normal colon epithelium (n = 60), and
adenomatous polyps (n = 34). The array was deparaffinized, rehy-
drated, treated with 3% hydrogen peroxide, blocked with 10% nor-
mal goat serum, incubated with the 820 TβRIII custom polyclonal
antibody at 4°C overnight, and incubated with antirabbit IgG-HRP
antibody (Vector Laboratories, Burlingame, CA). Cells were counter-
stained using hematoxylin. The immunoreactivity for TβRIII was
semiquantitatively scored by two independent observers in a blinded
manner, with staining intensity defined as 0 to 1 (no or weak staining),
2 (moderate staining), and 3 (intense staining). All images were acquired
at a magnification of ×20.
Cell Culture, Stable Cell Lines, and Adenoviral Infection
Human colon cancer cell lines HT29, SW480, and SW620 were
cultured in McCoy 5A + 10% fetal bovine serum (FBS) and high-
glucose Dulbecco modified Eagle medium + 10% FBS, respectively.
HT29 stable cell lines, representing a pool of stable clones, were de-
rived as previously described and maintained in 500 μg/ml G418
[37,40]. Adenoviral infections were performed as previously de-
scribed [39]. All adenoviral infections were performed at a multiplic-
ity of infection of 25 for all constructs. Cells were treated with the Ras
antagonist farnesyl thiosalicylic acid (FTS) at 200 μM or dimethyl sulf-
oxide (DMSO) control for 3 days before harvest. Media and FTS were
changed daily to maintain the correct concentration of FTS.
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TGF-β Binding and Cross-linking
TGF-β binding and cross-linking experiments were performed as
previously described [37,39].
Western Blot Analysis
A total of 2.5 × 105 cells were plated in six-well dishes and allowed
to recover. Cells were serum-starved overnight and then treated with
100 pM TGF-β or 20 nM BMP-2 for the indicated times. The cells
were lysed in boiling sample buffer and resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and immunoblotted for the
proteins of interest. Primary antibodies (p-Smad1/5/8 [no. 9511],
Smad1 [no. 9743], p-Smad2 [no. 3101], Smad2 [no. 3103], pp44/
42 [no. 9101], p44/42 [no. 9102], p-p38 [no. 4511], and p38 [no.
9212]) were purchased from Cell Signaling Technology (Danvers,
MA), and a 1:1000 dilution was used for immunoblot analysis. Pri-
mary Ras antibody (no. OP40) was purchased from EMD Chemicals
(Gibbstown, NJ), and a 1:2000 dilution was just for immunoblot
analysis. Protein levels were determined by immunoblot analysis fol-
lowed by densitometric analysis, including background subtraction
and normalization to β-actin using ImageJ software (NIH).
Proliferation Assay
HT29-Neo and HT29-TβRIII cells were plated at 3000 cells per
well in a 96-well plate and grown overnight with ligand stimulation
(20 nM BMP-2, 40 nM BMP-2, 50 pM TGF-β, or 100 pM TGF-β).
The next day, cells were pulsed with 1 μCi of 3H per well for 4 hours
at 37°C. Cells were washed in cold PBS and 10% trichloroacetic acid
(TCA) and then incubated for 1 hour at 4°C with 10% TCA. Cells
were then washed with cold 10% TCA and lysed overnight with 0.2M
NaOH. Lysates were then read on a scintillation counter.
Soft Agar Assay
Six-well plates were coated with a 0.8% base layer of agarose in
McCoy 5A medium with 10% FBS, L-glutamine, and 500 μg/ml
G418. HT29-Neo and HT29-TβRIII cells were counted and plated
at 6 × 103 cells/ml in 0.4% agar in McCoy 5A medium with 10%
FBS, L-glutamine, and 500 mg/ml G418. Cells were incubated at
37°C for 21 days and fed every 3 days with McCoy 5A + 10%
FBS + ligand. Cells were fixed and stained with 0.005% crystal vio-
let in 10% neutral buffered formalin solution, then washed with
PBS. Colonies were counted and quantified using Bio-Rad Quantity
One software (Hercules, CA).
Fibronectin Transwell Motility Assay
To assess migration, 2.5 × 105 cells were seeded in serum-free me-
dium in the upper chamber of a transwell filter, coated both at the
top and bottom with 50 μg/ml fibronectin (Calbiochem, La Jolla,
CA). Cells were untreated, treated with 100 pM TGF-β or 20 nM
BMP-2 and were allowed to migrate for 12 hours at 37°C through the
fibronectin toward the lower chamber containing medium plus 10%
FBS. Cells on the upper surface of the filter were removed, and cells
that migrated to the underside of the filter were fixed and stained using
the 3-Step Stain Set (Richard-Allan Scientific, Kalamazoo, MI). Each
assay was performed in duplicate, and each experiment was conducted
at least three times with three random fields from a 20× magnifica-
tion analyzed for each membrane. Data analysis was performed using
ImageJ software (NIH).
Monolayer Wound Healing Motility Assay
HT29-Neo, HT29-TβRIII, HT29-NTC, and HT29-shRNA-
TβRIII cells were plated to confluence and then scratched to cause
a wound. Cells were untreated, treated with 40 nM BMP-2, 100 pM
TGF-β, with or without 5 μM SB431542 or 15 μM SB203580, for
24 hours. Images were taken at 0- and 24-hour time points with a Nikon
inverted microscope (Melville, NY) at a magnification of ×10. Cells
were maintained in their selection medium at 37°C, 5% CO2 during
incubation. The percentage of wound closure was calculated ± SEM.
Immunofluorescence
For actin staining, the cells were fixed in a 4% parformaldehdye
and permeabilized with 0.1% Triton X for 5 minutes. Blocking was
performed with 1% bovine serum albumin, and cells were incubated
with a 1:50 dilution of phalloidin conjugated to Texas red (Molec-
ular Probes, Carlsbad, CA). For E-cadherin staining, the cells were
fixed with a 1:1 solution of methanol and acetone at −20°C. Block-
ing was performed with 1% bovine serum albumin, and cells were
incubated with a 1:250 dilution of E-cadherin antibody (BD Biosci-
ences, Madison, WI), followed by incubation with an antimouse
antibody conjugated to Texas Red (Molecular Probes). Immunoflu-
orescence images were obtained using a Nikon inverted microscope
at a magnification of ×60. Line scan analysis was performed using
ImageJ software (NIH).
HT29 Xenograft Model
All animal procedures were approved by the Institutional Animal
Care and Use Committee of Duke University. HT29-Neo or TβRIII
cells were grown in McCoy 5A + 10% FBS under the selection of
G418 (500 μg/ml). Twenty-four hours before injection, cells were
transferred to selection-free media. TβRIII expression was confirmed
by [125I]TGF-β binding and cross-linking. A total of 1 × 106 low–
passage number (P10) HT29-Neo or HT29-TβRIII cells were
injected subcutaneously into the right and left flanks of BALB/
cAnNCr nu/nu mice. Mice were weighed, and tumor width (W )
and length (L) were measured every 3 days. Tumor volume was de-
termined using the formula: V = 0.5 × L × W 2. Mice were followed
for 21 days, when some mice reached humane end points. On sac-
rifice, tumors were excised, weighed, and fixed in 4% paraformalde-
hyde for 2 hours followed by 70% ethanol. In addition, the lungs,
liver, and axillary lymph nodes were harvested and fixed in 4% para-
formaldehyde for 2 hours followed by 70% ethanol to determine the
sites of metastases. Tumors, lungs, livers, and lymph nodes were
stained with hematoxylin and eosin to examine histology and to de-
termine metastatic incidence.
Results
TβRIII Expression Is Increased in Human Colon Cancer
A decrease in TβRIII expression, both at the mRNA and protein
levels, has been demonstrated in multiple human cancer types, in-
cluding breast, kidney, non–small cell lung, ovarian, pancreatic, and
prostate cancers [37–42]. As alterations in both TGF-β and BMP sig-
naling have been demonstrated to contribute to colon carcinogenesis,
we examined the expression of TβRIII in human colon cancer using
a cDNA array with matched normal and colon carcinoma tissue
(Figure 1A). In contrast to what has been reported in other tumor
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types, there was no significant difference in average TβRIII mRNA
expression between normal tissue and colon carcinomas (Figure 1B).
In addition, no difference in TβRIII expression was observed with re-
gard to stage or grade of tumors (data not shown). We then examined
TβRIII expression at the protein level in human colon cancer speci-
mens by performing immunohistochemistry (IHC) for TβRIII on
human tissue microarrays containing normal colon epithelium (n =
60), adenomatous polyp tissue (n = 34), and colon carcinomas (n =
323; Figure 1, C and D). When comparing TβRIII protein expres-
sion between normal colon epithelium and colon carcinomas, a mod-
est but significant increase in TβRIII protein levels was observed
(Figure 1D). Comparison between matched normal and tumor pairs
(n = 25) demonstrates that whereas 8% of the matched pairs had no
change and 36% had a decrease in TβRIII expression, the majority
(56%) had an increase in TβRIII protein expression (Figure 1, E
and F). These data demonstrate that TβRIII expression is not signif-
icantly altered at the mRNA level in human colon cancer, whereas
TβRIII protein expression increases in a large subset of colon tumors,
suggesting posttranscriptional regulation of TβRIII expression in hu-
man colon cancer.
TβRIII Enhances Signaling in Colon Cancer Cells
To investigate the role of TβRIII in colon cancer, several colon
cancer cell lines were analyzed for TβRIII expression. HT29, a
Smad4-positive cell line derived from a primary colon carcinoma,
and SW480 and SW620 cells, Smad4-deficient cell lines that are de-
rived from the primary colon cancer (SW480) and metastatic lymph
node (SW620) from the same patient, all express TβRIII, albeit with
different patterns of posttranslational modification (Figure 2A). To
examine the effects of an increase in TβRIII expression on colon
cancer, HT29 colon cancer cell lines stably expressing Neo or TβRIII
were created, and TβRIII expression was verified by binding and
cross-linking 125I-TGF-β (Figure 2, A and B). The expression of both
membrane-bound TβRIII and sTβRIII was increased in HT29-
TβRIII cells relative to HT29-Neo cells (Figure 2B).
Figure 1. TβRIII expression increases during colon cancer. (A) A cDNA array with matched normal and colon tumors (n = 37) was
hybridized with a [32P]-labeled probe for TβRIII. The signal intensity for each spot was determined using ImageJ software. Boxed areas
represent paired normal, tumor, and metastases. (B) Graphical representation of the mean signal intensity ± SD of the intensity. NS
indicates not significant. (C) TβRIII IHC was performed on a human tissue microarray of normal colon and tumor specimens. The tissue
array was scored on a scale of 0 (no staining) to 3 (highest). Adenomatous colon polyp (n= 34), normal tissue (n= 60), and colon cancer
(n = 323). Original magnification, ×20. (D) Graphical representation of the average intensity score of TβRIII protein expression in normal
and tumor tissues ± SEM. (E) TβRIII IHC was performed on a human tissue microarray of normal colon and tumor specimens. Repre-
sentative matched normal and tumor sample pairs from the same patient are shown, demonstrating no change, an increase, or a de-
crease in TβRIII expression. Original magnification, ×20. (F) Graphical representation of the percentage of matched pairs (n = 25) that
demonstrate an increase (n = 14), no change (n = 2), or decrease (n = 9) in TβRIII protein expression in tumor versus normal tissue.
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Restoring TβRIII expression has been demonstrated to inhibit
TGF-β responsiveness in other cancer types, including in breast cancer,
as well as inhibiting BMP responsiveness in pancreatic cancer [37,43].
To determine whether increased expression of TβRIII alters TGF-β or
BMP-2 responsiveness, phosphorylation of Smad2, Smad1/5/8, p38,
and ERK in response to ligand stimulation was examined in HT29-
Neo and HT29-TβRIII Smad4-expressing colon cancer cells. There
was a significant increase in basal levels of p-Smad1/5/8 in HT29-
TβRIII cells in the absence of exogenous ligand treatment (Figure 2C).
In response to TGF-β1, p-Smad2, p-Smad1/5/8, and p-p38 levels
were increased in HT29-TβRIII cells relative to HT29-Neo cells, with
an earlier onset of Smad2 phosphorylation (Figure 2C ). In response
to BMP-2, HT29-TβRIII cells exhibited an earlier onset of Smad1/
5/8 phosphorylation and increased p-p38 signaling (Figure 2C ). No
change in ERK signaling was observed, basally or with ligand treat-
ment. These data suggest that TβRIII has both ligand-independent
and ligand-dependent effects on signaling because Smad1/5/8 phos-
phorylation was enhanced both basally and in response to exogenous
ligand treatment, and Smad2 and p38 enhancement was ligand spe-
cific. Together, these data demonstrate that TβRIII increases TGF-β–
and BMP-2–mediated canonical and noncanonical signaling in colon
cancer cells, in stark contrast to the inhibitory effects of TβRIII on
TGF-β superfamily signaling in other cancer contexts [37,39].
TβRIII Increases Ligand-Stimulated Proliferation in Colon
Cancer Cells by Decreasing Basal and Ligand-Stimulated
p21 and p27 Expression
TGF-β treatment in the presence of oncogenic K-Ras, which regu-
lates posttranslational modification of TβRIII, has been demonstrated
to induce proliferation and downregulate p21 in colon cancer cells
[27,36]. To examine the effects of TβRIII expression on proliferation,
HT29-Neo and TβRIII cells were treated with BMP-2 or TGF-β and
proliferation was examined by 3H-thymidine incorporation. In the
absence of ligand stimulation, no significant difference was observed
in proliferation between HT29-Neo and TβRIII cells (Figure 3, A
and B). However, TGF-β1 or BMP-2 treatment resulted in moderate
growth arrest in HT29-Neo cells (10%-15% reduction in growth with
TGF-β1 treatment and 7%-15% reduction with BMP-2 treatment)
(Figure 3, A and B). In contrast, treatment of HT29-TβRIII cells
with either BMP-2 or TGF-β resulted in resistance to ligand-induced
growth arrest and a modest, but significant increase in cell growth
(≥5% increase in growth with both TGF-β1 and BMP treatment;
Figure 2. TβRIII is expressed in colon cancer cell lines and enhances BMP-2– and TGF-β–mediated signaling. (A) Binding and cross-
linking of total cell lysates (TCL) (left lanes) and immunoprecipitation (IP) for TβRIII (right lanes) from four different cell lines: HT29 stable
cell lines, namely, HT29-Neo and HT29-TβRIII; SW480 cells, derived from a primary colorectal adenocarcinoma; and SW620 cells, de-
rived from the metastatic lymph node site of a colorectal adenocarcinoma from the same patient as the SW480 line. (B) Expression of
sTβRIII in HT29 stable cell lines. Cells were grown in 10% FBS McCoy 5A for 24 hours. TβRIII and sTβRIII expression was examined in
cells and medium by binding and cross-linking. β-Actin serves as a total protein control (bottom panel). (C) HT29-Neo and TβRIII cells
were serum-starved overnight and then treated with 100 pM TGF-β or 20 nM BMP-2 during the indicated time course (minutes). Western
blot analyses were performed for the indicated proteins. Densitometric analysis is shown normalized to β-actin.
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Figure 3. TβRIII expression increases colon cancer in vitro tumorigenicity. (A) HT29-Neo and TβRIII cells were treated with 20 or 40 nM
BMP-2 for 24 hours. Proliferation was analyzed by a 3H incorporation assay. The percent proliferation was determined by normalizing the
counts to those of untreated samples. (B) HT29-Neo and TβRIII cells were treated with 50 or 100 pM TGF-β1 for 24 hours. Proliferation
was analyzed by a 3H incorporation assay. (C) HT29-Neo and TβRIII cells were treated with 2 or 10 nM BMP-2 and 50 or 100 pM TGF-β1
for 24 hours. HT29-Neo and TβRIII cells were treated with 200 μM FTS or DMSO for 3 days. Western blot analyses were performed to
analyze protein levels of p21, p27, p15, cyclin D, and Ras with β-actin as a total protein control. (D) HT29-Neo and TβRIII cells were plated
in a soft agar assay untreated or treated with 20 nM BMP-2, 40 nM BMP-2, 50 pM TGF-β, or 100 pM TGF-β for 21 days. The mean
percent colony formation ± SEM is shown normalized to the untreated Neo or TβRIII. Average colony number is shown above the bar
graph. (E) HT29-Neo and TβRIII cells were treated with 40 nM BMP-2 or 100 pM TGF-β for 48 hours and examined for apoptosis by
Western blot analysis of caspase 9 levels. Densitometric analysis is shown normalized to β-actin. (F) HT29-Neo and TβRIII cells were
treated with 50 μM 5-fluorouracil for 48 hours. Cells were concurrently treated with 20 nM BMP-2 or 100 pM TGF-β and examined for
apoptosis induction by Western blot analysis of PARP cleavage. Densitometric analysis is shown normalized to β-actin.
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Figure 3, A and B). Although there is a modest increase in proliferation
in the HT29-TβRIII ligand–treated cells, these differences are signifi-
cant (Student’s t test, P < .05) in comparison to the reduction in pro-
liferation observed in the HT29-Neo ligand–treated cells. These data
demonstrate that TβRIII can inhibit ligand-mediated growth arrest
and stimulate proliferation in response to TGF-β or BMP-2 in colon
cancer cells. Similar results were obtained in the SW480 cells in re-
sponse to BMP treatment (Figure W1C ).
TGF-β and BMP regulate proliferation through induction of a
number of cell cycle proteins, including the cyclin-dependent kinase
inhibitor, p21 [44]. To explore the mechanism by which TβRIII reg-
ulates colon cancer cell proliferation, the effect of TβRIII on p21,
p27, cyclin D, and p15 levels was examined. In response to treat-
ment with either BMP-2 or TGF-β1, p21 and p27 protein levels in-
creased with no change in cyclin D1 or p15 levels in HT29-Neo cells
(Figure 3C ). SW480-GFP cells exhibit a modest increase in levels of
p27 in response to TGF-β treatment and a modest decrease in p21
levels in response to BMP-2 ligand stimulation (Figure W1B). In
contrast, HT29-TβRIII cells exhibit a reduction in basal p21 levels
relative to HT29-Neo cells and neither BMP-2 nor TGF-β induced
p21 or p27 expression (Figure 3C ). Similarly, SW480-TβRIII cells
exhibited a reduction in basal p21 levels relative to SW480-GFP
cells, and TGF-β treatment failed to stimulate p27 expression (Fig-
ure W1B). Interestingly, no significant alterations in p21 mRNA
levels were observed in the HT29-Neo or HT29-TβRIII cell lines
in response to TGF-β or BMP-2 treatment (Figure W1A), suggesting
that TβRIII promotes proliferation in colon cancer cells through the
down-regulation of p21 at the protein level.
As oncogenic K-Ras, which regulates posttranslational modifica-
tion of TβRIII, has been demonstrated to induce proliferation and
downregulate p21 in colon cancer cells, we examined the contribu-
tion of Ras signaling to TβRIII-mediated decreases in p21 levels by
using the Ras inhibitor, FTS [27,36,45]. As previously observed, treat-
ment with FTS inhibits Ras and significantly upregulates p21 protein
levels in HT29-Neo and HT29-TβRIII cells (Figure 3C) [45]. Inhi-
bition of Ras by FTS treatment also attenuates TβRIII-mediated inhi-
bition of ligand-induced p21 levels, suggesting that TβRIII-mediated
regulation of p21 occurs at least partially in a Ras-dependent manner
in colon cancer cells (Figure 3C).
TβRIII Increases Colon Cancer Cell Tumorigenicity In Vitro
To examine the effect of TβRIII on anchorage-independent colon
cancer cell growth, a soft agar assay was performed with HT29-Neo
and HT29-TβRIII cells. In the absence of ligand stimulation, no dif-
ference in colony formation was observed between HT29-Neo and
TβRIII cells (Figure 3D). In response to either BMP-2 or TGF-β treat-
ment, HT29-Neo cells had a modest but significant decrease in colony
formation. In contrast, in HT29-TβRIII cells colony formation signif-
icantly increased in response to ligand stimulation (Figure 3D). These
data demonstrate that TβRIII expression enhances ligand-stimulated
anchorage-independent growth, a hallmark of tumorigenicity, in colon
cancer cells.
TGF-β signaling has been demonstrated to regulate apoptosis, with
resistance to apoptosis being another characteristic of tumorigenicity.
Although increasing TβRIII expression only modestly decreased anoikis
in HT29 cells (data not shown), increasing TβRIII expression signifi-
cantly reduced ligand-induced apoptosis, as demonstrated by decreased
levels of caspase 9 in HT29 cells (Figure 3E). In addition, the expres-
sion of TβRIII inhibited chemotherapy (5-fluorouracil)-induced apop-
tosis in HT29 cells (Figure 3F). These data demonstrate that TβRIII
can inhibit ligand-induced and chemotherapy-induced apoptosis and
may inhibit anoikis. This resistance to apoptosis supports a protumori-
genic role for TβRIII in colon cancer.
TβRIII Increases Colon Cancer Cell Motility
TβRIII has been demonstrated to regulate cell motility and in-
vasion in both epithelial and cancer cells [13,37,38]. In the context
of other cancers, the ability to inhibit cell motility and invasion plays
an important role in TβRIII’s function as a suppressor of cancer
progression. The increased tumorigenicity observed in colon cancer
cells with increased TβRIII expression in vitro suggests that TβRIII
may regulate motility in colon cancer cells as well. A fibronectin
transwell migration assay demonstrated a trend toward an increase
in basal migration of SW480-TβRIII and SW620-TβRIII cells in
the absence of ligand stimulation, whereas TGF-β– and BMP-2–
treated SW480-TβRIII and SW620-TβRIII cells had a significant
increase in motility in comparison to GFP-infected control cells
(Figures 4A and W3). However, no further increase in migration
is observed between untreated and ligand-stimulated TβRIII cells,
suggesting that TβRIII mediates an increase in basal migration. In
addition, HT29-TβRIII cells consistently migrated faster than the
HT29-Neo cells in response to ligand treatment in a monolayer
wound healing assay (Figure 4B). In a reciprocal manner, short hairpin
RNA (shRNA)–mediated silencing of endogenous TβRIII significantly
decreased both basal and ligand-induced migration in HT29 cells
(Figure 4B). In addition, knockdown of TβRIII in SW480 and
SW620 cells demonstrated a trend toward a decrease in migration
in a fibronectin transwell migration assay, with a significant reduction
in migration on BMP ligand stimulation in SW620 cells (Figures 4A
and W3).
As TβRIII expression in colon cancer cells enhanced both Smad and
p38 signaling (Figure 2), we examined the contribution of these path-
ways to TβRIII-mediated stimulation of migration. HT29-Neo or
TβRIII cells were treated with the ALK5 inhibitor SB431542 or the
p38 inhibitor SB203580, and effects on migration were assessed in a
monolayer wound healing assay. The ALK5 inhibitor and the p38 in-
hibitor both inhibited TβRIII-mediated stimulation of migration (Fig-
ure 4C ). On treatment with either the ALK5 inhibitor SB431542 or
the p38 inhibitor SB203580, HT29-TβRII cells migrated at a rate com-
parable to HT29-Neo cells and did not demonstrate a ligand-induced
increase in migration. This suggests that TβRIII regulates migration in
colon cancer cells through both the canonical (ALK5) and noncanonical
(p38) TGF-β signaling pathways.
Reorganization of the actin cytoskeleton occurs during most types
of cell migration. TGF-β has been demonstrated to induce activation
of the actin cytoskeleton [46,47]. Loss of cell-cell junctions can also
occur during cell migration, which can be followed by the loss or de-
creased expression of the cell junction protein E-cadherin [47]. Con-
sistent with an increased migratory phenotype, HT29-TβRIII cells
exhibit alterations in actin and E-cadherin staining relative to HT29-
Neo cells (Figure 5, A and B). Although HT29-Neo cells demonstrated
organized actin and E-cadherin staining with cuboidal cell morphology,
sharply defined cell-cell contacts and a smooth edge along the wound
and in confluent areas of the culture (Figure 5, A and B), HT29-TβRIII
cells exhibited a more elongated cell phenotype, with disorganized actin
and E-cadherin staining, more diffuse localization and a decrease in
staining at cell-cell junctions (Figure 5, A and B). In addition,
HT29-TβRIII cells formed lamellipodia with membrane ruffling along
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Figure 4. TβRIII increases colon cancer cell migration. (A) SW480 and SW620 GFP, TβRIII, NTC, or shTβRIII adenovirally infected cells were
plated in a fibronectin transwell migration assay. Cells were plated in serum-free conditions on a fibronectin-coated transwell (50 μg/ml)
with and without ligand treatment. Migration toward serum was measured by counting the number of cells on the filter after 12 hours. Fold
change±SEM is demonstrated. *P< .05. NS indicates not significant. (B) HT29-Neo, TβRIII, and NTC (nontargeting control) or shRNA TβRIII
adenovirally infected cellswere plated in amonolayer scratchwound assay. Cellswere grown to confluence and thenwounded by scratching
and treated with 40 nM BMP-2 or 100 pM TGF-β. The percent migration was calculated by measuring the wound closure over time (0 and
24 hours). (C) Scratch wound assay with HT29-Neo and TβRIII cells treated with ligand and the ALK5 inhibitor SB431542 (5 μM) or the p38
inhibitor SB203580 (15 μM). The percent migration was calculated by measuring the wound closure over time (0 and 24 hours). *P = .02
RIII UT versusRIII UT+SB431542. **P= .01RIII 100 pMTGF-β versusRIII 100 pMTGF-β+SB431542, RIII UT versusRIII UT+SB203580, RIII
100 pM TGF-β versus RIII 100 pM TGF-β+ SB203580. Western blot analysis showing inhibition of TGF-β signaling with inhibitor treatment.
Cells were treated with 100 pM TGF-β for 40 minutes, with or without DMSO, 5 μM SB431542 or 15 μM SB203580 treatment.
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the scratch edge, which was not observed in the HT29-Neo cells.
Whereas HT29-Neo cells demonstrated E-cadherin staining along
the edge of the wound, HT29-TβRIII cells lacked E-cadherin stain-
ing in cells lining the edge of the wound, as demonstrated by line
scan analysis of E-cadherin intensity across individual cells (Figure 5B).
Collectively, these data support a TβRIII-mediated increase in colon
cancer cell migration, which stands in contrast to the effect of TβRIII
in other cancer cell lines where TβRIII expression significantly inhibits
both motility and invasiveness [13,37,38].
TβRIII Enhances Early Colon Cancer Tumorigenicity In Vivo
The expression of TβRIII in colon cancer cells increased tumorige-
nicity in vitro, with increased proliferation and cell migration and a
Figure 5. TβRIII alters actin and E-cadherin localization in colon cancer cells. (A) Actin (phalloidin) immunofluorescent staining. HT29-Neo
and TβRIII cells were grown to confluence and then wounded by scratching and treated with 40 nM BMP-2 or 100 pM TGF-β. At 18 hours
after scratch, cells were fixed and stained for actin. Images show actin staining in confluent culture (a, d, g, j, m, p) and along the wound
edge (b, e, h, k, n, q). Original magnification, ×60. Boxed area (b, e, h, k, n, q) is shown enlarged in c, f, i, l, o, r. (B) E-cadherin immuno-
fluorescent staining. HT29-Neo and TβRIII cells were grown to confluence and then wounded by scratching and treated with 40 nM BMP-2
or 100 pM TGF-β. At 18 hours after scratch, cells were fixed and stained for E-cadherin. Images show E-cadherin staining in confluent
culture (a, d, g, j, m, p) and along the wound edge (b, e, h, k, n, q). Original magnification, ×60. Boxed area (b, e, h, k, n, q) is shown
enlarged in c, f, i, l, o, r. Line scan analysis of individual cells (ImageJ software; NIH) shows E-cadherin staining intensity in a single cell from
the interior toward the wound edge. The line demonstrates the area of measured intensity.
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reduction in apoptosis in response to ligand. To investigate the in vivo
effects of TβRIII on tumorigenicity, we performed xenograft studies
with the HT29 stable cell lines. HT29-Neo and HT29-TβRIII cells
were injected subcutaneously into the flanks of female Balb/c Nu/Nu
mice, and tumor volume was measured every 3 days. Early in the study,
HT29-TβRIII tumors were significantly larger than the HT29-Neo
tumors (day 9; Figure 6B). However, by day 21, no significant differ-
ence in tumor volume or tumor mass was observed between HT29-
Neo and TβRIII tumors (Figure 6, B and C), and no metastases were
observed in either HT29-Neo or HT29-TβRIII xenograft mice. TβRIII
expression was examined by IHC (day 21 tumors), and all HT29-
TβRIII tumors maintained TβRIII overexpression in comparison to
HT29-Neo tumors (Figure 6A). These results suggest that TβRIII en-
hances early tumorigenicity in vivo but that other factors may com-
pensate to ameliorate these effects during cancer progression in this
model system.
Discussion
In this study, we demonstrate that, in contrast to cancers of the breast,
kidney, lung, ovary, pancreas, and prostate where TβRIII expression is
decreased, in human colon cancer, TβRIII expression is not significantly
altered at the mRNA level and is increased at the protein level. In
colon cancer cells, increasing TβRIII expression enhanced both TGF-
β– and BMP-2–induced signaling, including phosphorylation of p38,
Smads 1/5/8, and Smad2. Further, TβRIII induced resistance to ligand-
mediated growth arrest, increased proliferation through a decrease in
p21 induction and increased in vitro tumorigenicity in response to
either BMP or TGF-β treatment as well as in vivo tumorigenicity at
early time points. The increase in tumorigenicity is due to a TβRIII-
mediated resistance to ligand- and chemotherapy-induced apoptosis,
increased anchorage-independent cell growth, and increased cell mi-
gration. Collectively, these data suggest a role for TβRIII as a mediator
of TGF-β superfamily function during colon cancer progression.
Figure 6. TβRIII enhances early colon cancer tumorigenicity in vivo. A total of 1 × 106 HT29-Neo or HT29-TβRIII colon cancer cells were
injected subcutaneously into the right and left flanks of BALB/cAnNCr nu/numice. Mice were weighed, and tumor width (W ) and length
(L) were measured every 3 days. Tumor volume was determined using the formula: V = 0.5 × L × W 2. (A) TβRIII IHC of HT29-Neo and
TβRIII tumors at day 21. (B) Graphical representation of HT29-Neo and TβRIII tumor volume over time (D indicates day). D9, *P = .004.
(C) Representative images of HT29-Neo and TβRIII xenograft tumors and graphical comparison of final tumor mass ± SEM of HT29-Neo
and TβRIII xenografts at day 21. NS indicates not significant.
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The maintenance and increase in TβRIII expression observed in
colon cancer in comparison to normal colon tissue is in striking con-
trast to what has been previously observed in multiple human cancer
types, including breast, lung, ovarian, pancreatic, and prostate cancers
[37–41], where TβRIII expression is lost early in cancer progression and
significantly inhibits metastasis, motility, invasion, and angiogenesis
through sTβRIII-mediated down-regulation of TGF-β signaling
[37,38,48,49]. In colon cancer, there is no significant change in
TβRIII expression at the mRNA level, whereas TβRIII protein ex-
pression is significantly increased in 56% of matched normal and tu-
mor pairs (Figure 1E ), suggesting posttranscriptional regulation of
TβRIII expression. Indeed, oncogenic K-Ras–dependent posttran-
scriptional regulation of TβRIII has been reported in colon cancer,
resulting in a more tumorigenic phenotype [36]. As K-Ras is mutated
in up to 50% of colon cancer patients, and these patients have a
worse prognosis [50], the current results suggest that TβRIII could
function downstream of oncogenic K-Ras to mediate this effect. Fur-
ther supporting this hypothesis is the attenuation of TβRIII-mediated
inhibition of ligand-induced p21 up-regulation in the presence of
the Ras inhibitor, FTS (Figure 3C ). The interaction of TβRIII and
the Ras pathway remains to be further explored.
How might sustained or increased TβRIII expression promote co-
lon cancer progression? We demonstrate here that increasing TβRIII
expression in colon cancer cells enhances both canonical and non-
canonical TGF-β superfamily signaling in colon cancer cells, with
an increase in the basal phosphorylation of Smad1/5/8 and both
BMP-2 and TGF-β ligand–enhanced phosphorylation of Smad2,
Smad1/5/8, and p38 (Figure 2). These results are consistent with
the well-established ligand presentation role of TβRIII, where TβRIII
binds TGF-β superfamily ligands and increases ligand binding to re-
spective type I and type II TGF-β superfamily receptors to enhance
signaling [6,51]. The enhancement of p38 signaling, as well as the
ability of TβRIII to regulate the biology of Smad4 deficient colon
cancer lines, both suggest that TβRIII has both Smad4-dependent
and -independent effects on signaling and biology in colon cancer
cells. As increased levels of TGF-β have been demonstrated to cor-
relate with increased proliferation and invasion of colon cancer cells
in vitro, disease progression, and a poorer prognosis for human colon
cancer patients [24,26–28], the ability for TβRIII to enhance TGF-β
superfamily signaling provides one potential mechanism for TβRIII
promoting colon cancer progression. These results are also consistent
with the observation that markers of BMP (i.e., ID1) and TGF-β
signaling (i.e., PAI-1) are increased in colon cancer tissue relative
to matched normal tissue (Figure W2). In contrast, TβRIII has been
previously demonstrated to downregulate Smad signaling in other tu-
mor types, in part through sTβRIII-mediated sequestration of ligand
[37]. Interestingly, in colon cancer, whereas TβRIII is shed to pro-
duce sTβRIII (Figure 2B), and increasing TβRIII expression does in-
crease the level of sTβRIII (Figure 2B), the level of sTβRIII relative to
TβRIII is relatively low compared with other cancer cell lines, includ-
ing breast cancer lines (data not shown) [37]. Thus, TβRIII may ex-
ert a different role in colon cancer than in other solid tumors owing
to the maintenance of expression during colon cancer progression
and the relative preservation of cell surface TβRIII relative to sTβRIII
in colon cancer.
Increased TβRIII-mediated TGF-β superfamily signaling seems to
promote colon cancer progression by altering numerous aspects of
colon cancer biology. Increased TβRIII expression enhances prolifer-
ation in response to treatment with either BMP-2 or TGF-β, largely
through TβRIII-mediated down-regulation of both basal and ligand-
induced p21 and p27 levels in HT29 cells and a decrease in basal
p21 levels and a lack of ligand-mediated increase in p27 levels in
SW480-TβRIII cells (Figures 3C and W1B). This alteration in p21
levels may occur through Smad4-mediated mechanisms or through
the TβRIII-mediated regulation of the noncanonical p38 pathway.
Treatment with the Ras inhibitor FTS attenuated this TβRIII-mediated
repression of ligand-induced p21, suggesting that this occurs, at least
partially, in a Ras-dependent manner (Figure 3C). Oncogenic K-Ras
has also been demonstrated to induce proliferation in response to
TGF-β, associated with down-regulation of p21 and PTEN [36], in
part through posttranscriptional regulation of TβRIII, further sup-
porting a role for TβRIII downstream of oncogenic K-Ras in colon
cancer. Expression of TβRIII in colon cancer cells also confers an in-
crease in anchorage independent growth. Although this may be due in
part to increased proliferation, we also noted TβRIII-mediated re-
sistance to ligand-induced apoptosis, which may contribute to the en-
hanced colony formation (Figure 3).
The effects of TβRIII on promoting resistance to apoptosis in colon
cancer contrasts with the reported role for TβRIII in prostate and renal
cell cancer, where expression of TβRIII or treatment with sTβRIII has
been demonstrated to enhance apoptosis in vivo [9,42,52]. Similar to
the differences noted above, some of these alterations could be due
to the relative effect of sTβRIII versus full-length TβRIII. However,
at least in the context of renal cell cancer, the effects of TβRIII on
enhancing apoptosis were due to the cytoplasmic domain and medi-
ated through p38 phosphorylation [42]. Although the precise mecha-
nism by which TβRIII regulates apoptosis remains to be defined, the
divergent effects of TβRIII on apoptosis in different contexts further
highlights the context-dependent nature of TβRIII in regulating can-
cer biology.
The context-dependent effects of TβRIII are perhaps most striking
when examining the effects of TβRIII on migration. We have previ-
ously demonstrated that restoring TβRIII expression in breast, ovarian,
lung, pancreatic, and prostate cancer cells inhibits ligand-induced
migration [37–41,53], with robust effects on decreasing directional
persistence through activation of Cdc42 and increasing filopodia for-
mation [13]. Here we report that, in the context of colon cancer,
increasing TβRIII expression may enhance basal and significantly en-
hances ligand-induced migration, whereas shRNA-mediated silencing
of endogenous TβRIII expression inhibits both basal and ligand-
mediated cell migration, suggesting a role for TβRIII in both ligand-
dependent and -independent migration in colon cancer cells (Figures 4
and W3). We further demonstrate that TβRIII-mediated increases in
colon cancer cell migration are dependent on TβRIII-mediated en-
hancement of ALK-5 and/or p38 signaling, suggesting both Smad4-
dependent and -independent effects (Figure 4C ). Consistent with an
effect of increasing cell migration, increasing TβRIII expression in co-
lon cancer cells reorganized the actin cytoskeleton from predominantly
cell-cell junction localization to a more diffuse localization, increased
lamellipodia formation along a scratch wound edge, and decreased
E-cadherin staining at cell-cell junctions (Figure 5). Whereas TβRIII
seems to regulate cell migration through effects on the actin cytoskel-
eton in multiple cellular contexts, this seems to be mediated through
different pathways. Indeed, the ability of TβRIII to either increase or
decrease Smad-dependent signaling, to contribute to non-Smad sig-
naling, and to regulate signaling through the production of sTβRIII
provides multiple mechanisms by which TβRIII could differentially reg-
ulate cell migration in different contexts [4]. Current investigations are
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focused on elucidating the mechanistic basis for the context-dependent
effects of TβRIII on migration.
On the basis of the robust effects of TβRIII on enhancing ligand-
stimulated colony formation in soft agar (Figure 3D) and migration
(Figure 4), we were surprised to note only a modest, yet significant,
enhancement of colon cancer xenograft growth by TβRIII at early time
points (Figure 6), with no significant differences observed at later time
points. This enhancement is consistent with our in vitro observations
in colon cancer models and remains in stark contrast to the robust
inhibition of xenograft growth by TβRIII in lung and prostate cancer
models [38,41] and of breast cancer metastasis in a syngeneic model
[37]. The modest effect on colon cancer here may be due to alterations
in ligand-mediated effects occurring during in vivo tumorigenesis, a
lack of significant ligand stimulation in the xenograft model, the use
of a nonorthotopic xenograft model, or our inability to monitor the
effect on metastasis in the model system used. As the HT29 cell line
has been demonstrated to have a low engraftment rate with limited
metastasis when implanted orthotopically [54], an orthotopic study
may be limited in its ability to provide additional data on the effects
of TβRIII on colon cancer metastasis. Indeed, we have recently defined
important contributions of the host immune system in defining the
effects of TβRIII on cancer progression in vivo (B. Hanks and G.C.
Blobe, unpublished observations). Future studies will further explore
the context-dependent effects of TβRIII on cancer progression in
orthotopic, syngeneic murine models.
In conclusion, in contrast to other tumor types, TβRIII expression is
maintained and enhanced in human colon cancers and functions to pro-
mote colon cancer progression through promotion of proliferation,
migration, anchorage-independent growth, and resistance to apoptosis.
Taken together, these data suggest that similar to the role of TGF-β
superfamily signaling pathways, the role of TβRIII in regulating/mediating
cancer biology is cell type and context dependent. As such, targeting this
axis will require a more detailed understanding of the role TβRIII and the
entire TGF-β superfamily signaling pathway in human cancer biology.
References
[1] Massague J (2008). TGFβ in cancer. Cell 134, 215–230.
[2] Pardali K and Moustakas A (2007). Actions of TGF-β as tumor suppressor and
pro-metastatic factor in human cancer. Biochim Biophys Acta 1775, 21–62.
[3] Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K,
and Lopez-Casillas F (2001). Ligand binding and functional properties of beta-
glycan, a co-receptor of the transforming growth factor-β superfamily. Special-
ized binding regions for transforming growth factor-β and inhibin A. J Biol
Chem 276, 14588–14596.
[4] Gatza CE, Oh SY, and Blobe GC (2010). Roles for the type III TGF-β receptor
in human cancer. Cell Signal 22, 1163–1174.
[5] Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, and Blobe GC
(2008). Bone morphogenetic proteins signal through the transforming growth
factor-β type III receptor. J Biol Chem 283, 7628–7637.
[6] Lopez-Casillas F, Wrana JL, and Massague J (1993). Betaglycan presents ligand
to the TGF β signaling receptor. Cell 73, 1435–1444.
[7] Bernabeu C, Lopez-Novoa JM, and Quintanilla M (2009). The emerging role of
TGF-β superfamily coreceptors in cancer. Biochim Biophys Acta 1792, 954–973.
[8] Massague J (1998). TGF-β signal transduction. Annu Rev Biochem 67, 753–791.
[9] Margulis V, Maity T, Zhang XY, Cooper SJ, Copland JA, and Wood CG
(2008). Type III transforming growth factor-β (TGF-β) receptor mediates apop-
tosis in renal cell carcinoma independent of the canonical TGF-β signaling path-
way. Clin Cancer Res 14, 5722–5730.
[10] You HJ, Bruinsma MW, How T, Ostrander JH, and Blobe GC (2007). The
type III TGF-β receptor signals through both Smad3 and the p38 MAP kinase
pathways to contribute to inhibition of cell proliferation. Carcinogenesis 28,
2491–2500.
[11] Criswell TL and Arteaga CL (2007). Modulation of NFκB activity and E-cadherin
by the type III transforming growth factor β receptor regulates cell growth and
motility. J Biol Chem 282, 32491–32500.
[12] You HJ, How T, and Blobe GC (2009). The type III transforming growth factor-β
receptor negatively regulates nuclear factor κB signaling through its interaction
with β-arrestin2. Carcinogenesis 30, 1281–1287.
[13] Mythreye K and Blobe GC (2009). The type III TGF-β receptor regulates epithe-
lial and cancer cell migration through β-arrestin2–mediated activation of Cdc42.
Proc Natl Acad Sci USA 106, 8221–8226.
[14] Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernandez G, and
Lopez-Casillas F (2001). Recombinant soluble betaglycan is a potent and isoform-
selective transforming growth factor-β neutralizing agent. Biochem J 355, 215–222.
[15] Xu Y and Pasche B (2007). TGF-β signaling alterations and susceptibility to
colorectal cancer. Hum Mol Genet 16 Spec No 1, R14–R20.
[16] Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh
JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al. (1999). Mutational in-
activation of transforming growth factor β receptor type II in microsatellite stable
colon cancers. Cancer Res 59, 320–324.
[17] Howe JR, Bair JL, SayedMG, AndersonME,Mitros FA, Petersen GM, Velculescu
VE, Traverso G, and Vogelstein B (2001). Germline mutations of the gene encod-
ing bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28,
184–187.
[18] KodachLL,Wiercinska E, deMirandaNF,Bleuming SA,Musler AR, Peppelenbosch
MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, et al. (2008). The
bone morphogenetic protein pathway is inactivated in the majority of sporadic colo-
rectal cancers. Gastroenterology 134, 1332–1341.
[19] Neibergs HL, Hein DW, and Spratt JS (2002). Genetic profiling of colon can-
cer. J Surg Oncol 80, 204–213.
[20] Xie W, Rimm DL, Lin Y, Shih WJ, and Reiss M (2003). Loss of Smad signaling
in human colorectal cancer is associated with advanced disease and poor prog-
nosis. Cancer J 9, 302–312.
[21] Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, and Doetschman T
(1999). Transforming growth factor β1 suppresses nonmetastatic colon cancer at
an early stage of tumorigenesis. Cancer Res 59, 3379–3386.
[22] Hsu S, Huang F, Hafez M, Winawer S, and Friedman E (1994). Colon carci-
noma cells switch their response to transforming growth factor β1 with tumor
progression. Cell Growth Differ 5, 267–275.
[23] Warusavitarne J, McDougall F, de Silva K, Barnetson R, Messina M, Robinson
BG, and Schnitzler M (2009). Restoring TGFβ function in microsatellite un-
stable (MSI-H) colorectal cancer reduces tumourigenicity but increases metas-
tasis formation. Int J Colorectal Dis 24, 139–144.
[24] Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, and Cohen A (1995).
High levels of transforming growth factor β 1 correlate with disease progression
in human colon cancer. Cancer Epidemiol Biomarkers Prev 4, 549–554.
[25] Gregoire M, Garrigue L, Blottiere HM, Denis MG, and Meflah K (1992). Pos-
sible involvement of TGFβ1 in the distinct tumorigenic properties of two rat
colon carcinoma clones. Invasion Metastasis 12, 185–196.
[26] Robson H, Anderson E, James RD, and Schofield PF (1996). Transforming
growth factor β1 expression in human colorectal tumours: an independent prog-
nostic marker in a subgroup of poor prognosis patients. Br J Cancer 74, 753–758.
[27] Yan Z, Kim GY, Deng X, and Friedman E (2002). Transforming growth factor β1
induces proliferation in colon carcinoma cells by Ras-dependent, smad-independent
down-regulation of p21cip1. J Biol Chem 277, 9870–9879.
[28] Fujimoto K, Sheng H, Shao J, and Beauchamp RD (2001). Transforming growth
factor-β1 promotes invasiveness after cellular transformation with activated Ras in
intestinal epithelial cells. Exp Cell Res 266, 239–249.
[29] Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K,
and Mori M (2008). Clinical significance of BMP7 in human colorectal cancer.
Ann Surg Oncol 15, 1530–1537.
[30] Beck SE, Jung BH, Fiorino A, Gomez J, Rosario ED, Cabrera BL, Huang SC,
Chow JY, and Carethers JM (2006). Bone morphogenetic protein signaling and
growth suppression in colon cancer. Am J Physiol Gastrointest Liver Physiol 291,
G135–G145.
[31] Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, and Yang WL (2007).
Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and
promotes migration and invasion of HCT116 cells. Exp Cell Res 313, 1033–1044.
[32] Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande
JM, Keller JJ, Offerhaus GJ, Van Deventer SJ, and Peppelenbosch MP (2004).
Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial
cells in the colon. Gastroenterology 126, 111–121.
Neoplasia Vol. 13, No. 8, 2011 TβRIII and Colon Cancer Gatza et al. 769
[33] Nishanian TG, Kim JS, Foxworth A, and Waldman T (2004). Suppression of
tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4
in human cancer cells. Cancer Biol Ther 3, 667–675.
[34] Deng H, Ravikumar TS, and Yang WL (2009). Overexpression of bone mor-
phogenetic protein 4 enhances the invasiveness of Smad4-deficient human co-
lorectal cancer cells. Cancer Lett 281, 220–231.
[35] Deng X, Bellis S, Yan Z, and Friedman E (1999). Differential responsive-
ness to autocrine and exogenous transforming growth factor (TGF) β1 in
cells with nonfunctional TGF-β receptor type III. Cell Growth Differ 10,
11–18.
[36] Yan Z, Deng X, and Friedman E (2001). Oncogenic Ki-ras confers a more ag-
gressive colon cancer phenotype through modification of transforming growth
factor-β receptor III. J Biol Chem 276, 1555–1563.
[37] Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P,
Moeller BJ, Marks JR, and Blobe GC (2007). The type III TGF-β receptor
suppresses breast cancer progression. J Clin Invest 117, 206–217.
[38] Finger EC, Turley RS, Dong M, How T, Fields TA, and Blobe GC (2008).
TβRIII suppresses non–small cell lung cancer invasiveness and tumorigenicity.
Carcinogenesis 29, 528–535.
[39] Gordon KJ, Dong M, Chislock EM, Fields TA, and Blobe GC (2008). Loss of
type III transforming growth factor β receptor expression increases motility and
invasiveness associated with epithelial to mesenchymal transition during pancre-
atic cancer progression. Carcinogenesis 29, 252–262.
[40] Hempel N, How T, Dong M, Murphy SK, Fields TA, and Blobe GC (2007).
Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
Cancer Res 67, 5231–5238.
[41] Turley RS, Finger EC, Hempel N, How T, Fields TA, and Blobe GC (2007).
The type III transforming growth factor-β receptor as a novel tumor suppressor
gene in prostate cancer. Cancer Res 67, 1090–1098.
[42] Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, LeGrand
SN, Tamboli P, and Wood CG (2003). Genomic profiling identifies alterations
in TGFβ signaling through loss of TGFβ receptor expression in human renal cell
carcinogenesis and progression. Oncogene 22, 8053–8062.
[43] Gordon KJ, Kirkbride KC, How T, and Blobe GC (2009). Bone morphoge-
netic proteins induce pancreatic cancer cell invasiveness through a Smad1-
dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis
30, 238–248.
[44] Jakowlew SB (2006). Transforming growth factor-β in cancer and metastasis.
Cancer Metastasis Rev 25, 435–457.
[45] Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, and
Jansen B (2000). A novel Ras antagonist regulates both oncogenic Ras and the
tumor suppressor p53 in colon cancer cells. Mol Med 6, 693–704.
[46] Edlund S, Landstrom M, Heldin CH, and Aspenstrom P (2002). Transforming
growth factor-β–induced mobilization of actin cytoskeleton requires signaling by
small GTPases Cdc42 and RhoA. Mol Biol Cell 13, 902–914.
[47] Yamazaki D, Kurisu S, and Takenawa T (2005). Regulation of cancer cell mo-
tility through actin reorganization. Cancer Sci 96, 379–386.
[48] Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang
J, and Sun LZ (2002). Antitumor activity of a recombinant soluble betaglycan
in human breast cancer xenograft. Cancer Res 62, 4690–4695.
[49] Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA,
Luo J, Lopez-Casillas F, and Sun LZ (2002). Extracellular domain of TGFβ
type III receptor inhibits angiogenesis and tumor growth in human cancer cells.
Oncogene 21, 3541–3551.
[50] Benhattar J, Losi L, Chaubert P, Givel JC, and Costa J (1993). Prognostic signifi-
cance of K-rasmutations in colorectal carcinoma.Gastroenterology 104, 1044–1048.
[51] Lopez-Casillas F, Payne HM, Andres JL, and Massague J (1994). Betaglycan
can act as a dual modulator of TGF-β access to signaling receptors: mapping
of ligand binding and GAG attachment sites. J Cell Biol 124, 557–568.
[52] Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT, and Sun L
(2005). Systemic administration of a soluble betaglycan suppresses tumor
growth, angiogenesis, and matrix metalloproteinase-9 expression in a human
xenograft model of prostate cancer. Prostate 63, 81–90.
[53] Lee JD, Hempel N, Lee NY, and Blobe GC (2010). The type III TGF-β re-
ceptor suppresses breast cancer progression through GIPC-mediated inhibition
of TGF-β signaling. Carcinogenesis 31, 175–183.
[54] Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, and Fodstad O
(2004). Twelve colorectal cancer cell lines exhibit highly variable growth and
metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 40,
1593–1598.
770 TβRIII and Colon Cancer Gatza et al. Neoplasia Vol. 13, No. 8, 2011
Supplemental Methods
p21 Reverse Transcription–PCR
A total of 3 × 105 HT29-Neo and TβRIII cells were plated in a six-
well plate and allowed to recover. Cells were then treated with 10 nM
BMP-2, 40 nM BMP-2, 100 pM TGF-β, or 400 pM TGF-β for
24 hours. Total RNA was extracted using the RNeasy Mini Kit per
the manufacturer’s instructions (Qiagen, Valencia, CA). Half a micro-
gram of RNA was reverse transcribed using the SuperScript First-Strand
Synthesis System for reverse transcription–PCR (Invitrogen, Carlsbad,
CA). Each PCR contained 1 μg of cDNA along with p21 primers:
hp21, forward 5′ CAGGGGACAGCAGAGGAAGA 3′ and reverse
5′ TTAGGGCTTCCTCTTGGAGAA 3′; or hGAPDH, forward 5′
GAGTCAACGGATTTGGTCGT 3′ and reverse 5′ TTGATTTTG-
GAGGGATCTCG 3′ primers.
Western Blot Analyses
A total of 2.5 × 105 SW480 cells were plated in six-well plate and
allowed to recover, then adenovirally infected with GFP or FL-TβRIII-
GFP as described previously. At 36 hours after infection, cells were
treated with BMP-2 (2 and 10 nM) or TGF-β1 (50 or 100 pM)
for 24 hours. Western blot analyses were performed to analyze protein
levels of p21 (no. 2946; Cell Signaling Technology) and p27 (no. 2552;
Cell Signaling Technology) protein level with β-actin as a total pro-
tein control. Densitometric analysis, including background sub-
traction and normalization to β-actin, was performed using ImageJ
software (NIH).
Proliferation Assay
SW480 cells adenovirally infected with GFP or FL-TβRIII-GFP as
described previously and were plated at 3 × 103 cells per well in a 96-
well plate and grown overnight with ligand stimulation (20 nM BMP-
2, 40 nM BMP-2, 50 pM TGF-β, or 100 pM TGF-β). The next day,
cells were pulsed with 1 μCi of 3H per well for 4 hours at 37°C. Cells
were washed in cold PBS and 10% TCA and then incubated for 1 hour
at 4°C with 10% TCA. Cells were then washed with cold 10% TCA
and lysed overnight with 0.2 NaOH. Lysates were then read on a scin-
tillation counter.
ID1 and PAI-1 Expression Analysis
Matched normal colon mucosa and colon adenocarcinoma gene ex-
pression data (Affymetrix U133 Plus 2) from 32 patients were obtained
from the Gene Expression Omnibus (GEO) GSE8671. Raw expres-
sion data (.CEL) files were MAS5 normalized using Affymetrix Ex-
pression Console Version 1.0. MAS5 data were then log2 transformed
using the log transform function in MATLAB (release R2009a). To ex-
amine the differences in expression level between normal and tumor tis-
sue, the Affymetrix U133 Plus 2 probe set annotation file (release 24)
was acquired from the Affymetrix Web site, and probe sets were iden-
tified for each gene of interest. When multiple probes were present for
a given gene, probe expression levels were averaged for each sample. A
paired t test (GraphPad Prism 4.0; Graph Pad, Inc, La Jolla, CA) was
used to calculate differences in gene expression between matched nor-
mal mucosa and colon adenocarcinoma samples.










Figure W1. TβRIII does not alter p21 mRNA levels. (A) Reverse transcription–PCR analysis of p21 mRNA levels in HT29-Neo and TβRIII
cells. HT29-Neo and TβRIII cells were treated with 10 nM BMP-2, 40 nM BMP-2, 100 pM TGF-β, or 400 pM TGF-β for 24 hours. (B)
SW480 cells were adenovirally infected with GFP or FL-TβRIII-GFP. At 36 hours after infection, cells were treated with BMP-2 (2 and
10 nM) or TGF-β1 (50 or 100 pM) for 24 hours. Western blot analyses were performed to analyze levels of p21 and p27 proteins with
β-actin as a total protein control. Densitometric analysis is shown normalized to β-actin. (C) SW480 cells were adenovirally infected with
GFP or TβRIII-GFP. At 36 hours after infection, SW480 cells were treated with 20 and 40 nM BMP-2 or 50 and 100 pM TGF-β1 for
24 hours. Proliferation was analyzed by a 3H incorporation assay. The percent proliferation was determined by normalizing the counts
to those of untreated samples.
Figure W2. TGF-β and BMP response is enhanced in colon cancer. Box-and-whisker plot showing patterns of gene expression in patient
matched normal colon mucosa (gray) and colon adenocarcinoma (white). Colon adenocarcinoma samples show significantly lower lev-
els of TGF-β RIII (P= .0042, paired t test), but significantly higher levels of the BMP and TGF-β transcriptional targets ID1 (P< .0001) and
PAI-1 (P = .0143), respectively. No statistically significant differences in β-actin (P = .5957) levels were identified.
Figure W3. TβRIII increases colon cancer cell migration in a transwell migration assay. (A) Representative images of SW480 and SW620
GFP, TβRIII, NTC, or shTβRIII adenovirally infected cells were plated in a fibronectin transwell migration assay. Cells were plated in
serum-free conditions on a fibronectin-coated transwell (50 μg/ml) with and without ligand treatment. Original magnification, ×20.
